The 2017-18 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

Adam J. Fein, Ph.D.
Pembroke Consulting, Inc., and Drug Channels Institute

October 2017

LICENSE TERMS

This report is protected by copyright law. Unauthorized reproduction or distribution of this report or any portion of it may result in severe civil and criminal penalties and will be prosecuted to the maximum extent of the law. This report may be cited in commercial documents with full and appropriate attribution. Nothing in the license is intended to reduce, limit, or restrict any rights arising from fair use under copyright law or other applicable laws.


The complete End User License Agreement is available at:

Please contact us at admin@pembrokeconsulting.com if you would like to upgrade the license. You will pay only the difference in license fee.
ABOUT THE AUTHOR

Adam J. Fein, Ph.D., is the president of Pembroke Consulting, Inc., a management advisory and business research firm based in Philadelphia. He also is the CEO of Pembroke’s Drug Channels Institute, a leading management educator for and about the pharmaceutical industry.

Dr. Fein is one of the country’s foremost experts on pharmaceutical economics and the drug distribution system. Top manufacturers call on Dr. Fein’s insights and judgment to create successful commercial strategies and make better strategic decisions in our evolving healthcare environment.

Dr. Fein’s popular and influential Drug Channels website (www.DrugChannels.net) is the go-to source for definitive and comprehensive industry analysis, delivered with a witty edge. He has published hundreds of academic and industry articles, and is regularly quoted in such national publications as The Wall Street Journal, The New York Times, Forbes, and many others.

Dr. Fein earned his doctoral degree from the Wharton School of Business at the University of Pennsylvania and a B.A., summa cum laude, from Brandeis University. He lives in Philadelphia with his wife, Paula, and their two children.

Contact information
Adam J. Fein, Ph.D.
Pembroke Consulting, Inc.
1515 Market Street, Suite 960
Philadelphia, PA 19102
Phone: 215-523-5700
Website: www.PembrokeConsulting.com
Email: afein@pembrokeconsulting.com

Visit Dr. Fein’s Drug Channels blog for the latest industry updates!

www.DrugChannels.net
Drug Channels Institute (DCI), a division of Pembroke Consulting, Inc., is a leading provider of specialized management education for and about the pharmaceutical industry.

Drug Channels Institute combines Dr. Fein’s expertise and cutting-edge analysis—such as this 2017-18 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors—into comprehensive, interactive e-learning modules that offer your team a thorough grounding in crucial industry topics. These online learning tools explain highly complex economic and business data and concepts so you can:

- Make better decisions to achieve your business goals
- Improve relationships with key accounts
- Understand your customers, channels, and the economics of the U.S. pharmaceutical industry

View a module list at http://drugchannelsinstitute.com/products/e-learning-modules/.

DCI can code and brand any module for your company’s internal Learning Management System. Or you can get started quickly by letting us host your team via our online e-learning portal. DCI’s hosted e-learning modules are instantly viewable on all computer platforms, including iPads.

To learn more about how Drug Channels Institute can help your business, please contact:

Paula Fein, M.S.Ed.
V.P., Business Development
Drug Channels Institute
1515 Market Street, Suite 960
Philadelphia, PA 19102
Phone: 215-523-5700 x11
Website: www.drugchannelsinstitute.com
Email: paula@drugchannelsinstitute.com
INTRODUCTION AND GUIDE TO THIS REPORT

In 2017, pharmaceutical wholesalers confronted a deteriorating business environment. Many of the trends that we identified in previous editions of this report culminated in significant profit declines and loss of stock market value. Notable headwinds over the past year include:

- A slowdown in brand-name list price increases—and many manufacturers’ pledges to limit future increases
- Accelerating deflation in generic drug prices and the loss of excess profits earned during the generic inflation bubble
- Intense competition for the business of smaller pharmacies
- Ongoing concentration of dispensing market share for the traditional drugs dispensed by retail pharmacies and for the specialty drugs dispensed by specialty pharmacies
- Declining share of revenues from independent physician offices and clinics
- Lower-than-expected benefits from biosimilar drugs

Wholesalers have been trying to counter these negative trends with new pricing approaches, acquisitions, and other business strategies. Despite the profit pressures, the Big Three public wholesalers—AmerisourceBergen, McKesson, and Cardinal Health—remain among the largest U.S. corporations. We project that U.S. drug distribution revenues for these three companies will reach $425 billion in 2017.

This 2017–18 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors—our eighth edition—remains the most comprehensive tool for analyzing the economic and business realities of U.S. pharmaceutical distribution. In this definitive, nonpartisan resource, I explore and explain the industry’s interactions with—and services for—other participants in our healthcare system.

In this report, I have synthesized a wealth of statistical data, research studies, financial information, and my own business consulting experience. This unique resource will benefit pharmaceutical manufacturers, wholesalers, pharmacists, pharmacy owners, hospital executives, pharmacy buyers, benefit managers, managed care executives, policy analysts, investors, consultants, and many others.

Structure of the 2017-18 Report

The 2017-18 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors analyzes the industry in three major sections, comprising nine total chapters. It provides an up-to-date, fact-based analysis of this dynamic industry and how it works.

This year’s report retains the structure that we used in last year’s edition, and the chapters correspond to those of previous editions. Some sections and chapters have been expanded or reorganized to better cover the latest industry developments.
Here are some of the notable updates in the 2017-18 report:

- The Industry Overview (Chapter 1) has been reorganized and expanded to provide a more comprehensive introduction to the industry and its major participants.

- Our analysis and data on specialty drugs have been expanded to account for continued growth in this market segment. We have included additional data and analyses of specialty pharmacies operated by physician practices and hospitals.

- New analyses examine the payment relationships between the Big Three wholesalers and each of their larger customers.

- Our deconstruction of wholesaler buy-side and sell-side gross margins for drug distribution of brand-name drugs now includes separate estimates for: (1) wholesalers’ largest six pharmacy customers, (2) all other retail, mail, and specialty pharmacy customers, and (3) healthcare providers. The presentation of the generic drug figures now reflects sell-side discounts from published list prices.

- Additional historical trending information has been added throughout the report.

- Chapter 6 offers a more integrated presentation of significant forces of change.

We have updated all market and industry data with the most current information available. The 2017-18 edition also contains the latest financial data and market positions of the largest public companies: AmerisourceBergen, Cardinal Health, and McKesson. It updates our annual analysis of each wholesaler’s business segments and underlying business profitability, based upon our proprietary economic models. This information allows you to assess differences among the public wholesalers’ business organizations, strategies, and financial performance.

Here is a summary of the report’s main sections and chapters.

**PREFACE: INDUSTRY TRENDS AND KEY REPORT THEMES** provides an integrated overview of the major themes that recur throughout our analysis. Each theme includes links to relevant chapters and sections within the full report.

**SECTION I: WHOLESALER AND CUSTOMER INDUSTRY ANALYSIS**

- **Chapter 1: Industry Overview** (page 7) defines the industry, describes business differences between full-line wholesaling and specialty distribution, summarizes wholesalers’ obligations under the Drug Supply Chain Security Act (DSCSA), explains wholesalers’ channel roles, discusses and quantifies the products that wholesalers sell, and identifies the major industry participants and their revenues.
### Chapter 2: Channel Role for Retail, Mail, and Specialty Pharmacies

This chapter analyzes the pharmacy market—the customer group that accounts for the majority of wholesalers’ revenues. It covers wholesalers’ services for smaller pharmacies, wholesalers’ participation in the pharmacy-PBM relationship, and their interactions with pharmacy buying groups. The chapter then separately analyzes how wholesalers work with larger pharmacies, including our exclusive analysis of the large generic sourcing consortia between wholesalers and the largest pharmacies. Section 2.4, (page 49) analyzes wholesalers’ role in the distribution of patient-administered drugs that specialty pharmacies dispense. We also consider wholesaler-owned specialty pharmacies.

### Chapter 3: Channel Role for Physician Office/Clinics and Hospitals

This chapter examines channels for provider-administered medications, explains the buy-and-bill system for drugs administered in outpatient settings, and describes the role and functions that wholesalers perform for hospitals, including hospitals that participate in the 340B Drug Pricing Program. This chapter also provides an in-depth consideration of group purchasing organizations (GPOs) for both hospitals and physician practices. Chapter 3 has been expanded and reorganized from last year’s edition.

### Section II: Business Economics and Industry Trends

- **Chapter 4: Wholesaler Profitability** (page 82) delves into the industry’s income statement economics to explain the underlying sources of drug distribution profits. We deconstruct buy-side and sell-side gross margin components, distinguish sell-side profits from specialty and traditional drugs, and explain distribution service agreements (DSAs) with manufacturers. We analyze overall gross margins and operating profits. This chapter also explains how brand-name drug price inflation affects wholesalers’ profits.

- **Chapter 5: Financial Stability and Cash Management** (page 107) provides a detailed analysis of the key metrics that illustrate wholesalers’ overall financial health. These include capital structures, debt (leverage), balance sheet assets, cash flow, return on invested capital, and stock market valuation and performance.

- **Chapter 6: Forces of Change for Drug Distribution** (page 120) analyzes key industry trends that will impact the market structure and economics of the pharmaceutical wholesaling and specialty distribution industries. This chapter has been significantly revised and updated from last year’s edition.

### Section III: Big Three Wholesaler Company Profiles

In this section, we analyze the latest financial data and strategies of the largest public companies. Each chapter provides parallel examinations of the Big Three public wholesalers.
We scrutinize each company’s business history, acquisitions and divestitures, business mix, profitability, largest customers, and company-specific business trends.

- Chapter 7: AmerisourceBergen Corporation (page 151)
- Chapter 8: Cardinal Health (Page 168)
- Chapter 9: McKesson Corporation (page 181)

How to Use the 2017-18 Report

The chapters are self-contained and do not need to be read in order. We include extensive internal references to help you navigate the entire document and customize it to your specific needs. There are also more than 300 endnotes, most of which have hyperlinks to original source materials. The report also includes a list of the Acronyms and Abbreviations used within it.

Please note that highlighted internal references are clickable hyperlinks in the PDF document. After clicking a link, use the following shortcuts to return to your previous location in the document:

- Windows: ALT+Left Arrow
- Mac: Command+Left Arrow

To search the entire PDF document for every occurrence of a word or phrase, use the following keyboard shortcuts:

- Windows: Shift+CTRL+F
- Mac: Shift+Command+F

As always, I welcome your feedback. Please contact me if you have any questions or comments about The 2017-18 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors.

Adam J. Fein
October 2017

P.S. You can find post-publication errata here:
# CONTENTS

**PREFACE: INDUSTRY TRENDS AND KEY REPORT THEMES** ................................................................. 1

**SECTION I: WHOLESALER AND CUSTOMER INDUSTRY ANALYSIS** ........................................... 6

Chapter 1: Industry Overview ............................................................................................................. 7

1.1. Wholesale Industry Fundamentals ............................................................................................. 7
    1.1.1. Defining Drug Wholesale Distribution ............................................................................... 7
    1.1.2. Full-Line Wholesalers ..................................................................................................... 8
    1.1.3. Specialty Distributors .................................................................................................... 10
    1.1.4. Regulation and Supply Chain Security ............................................................................. 11

1.2. The Products That Wholesalers Sell ....................................................................................... 13
    1.2.1. Brand vs. Generic Drugs ............................................................................................... 13
    1.2.2. Route of Administration ............................................................................................... 14
    1.2.3. Specialty vs. Traditional Drugs ....................................................................................... 15
    1.2.4. Specialty Product Distribution ....................................................................................... 15

1.3. Overview of Wholesalers’ Channel Roles .............................................................................. 17
    1.3.1. Physical Distribution .................................................................................................... 17
    1.3.2. Financial Intermediation ............................................................................................... 18
    1.3.3. Services for Pharmacies, Providers, and Manufacturers ............................................... 19
    1.3.4. Impact on Pharmacy and Provider Reimbursement ....................................................... 20

1.4. Industry Participants ................................................................................................................. 21
    1.4.1. Big Three Wholesalers: Revenue and Growth Trends ................................................... 21
    1.4.2. Other Wholesale Market Participants ........................................................................... 23

Chapter 2: Channel Role for Retail, Mail, and Specialty Pharmacies ............................................... 25

2.1. The Pharmacy Market .............................................................................................................. 26
    2.1.1. Outpatient Dispensing Formats ....................................................................................... 26
    2.1.2. Pharmacy Market Size and Structure ............................................................................ 27
    2.1.3. Differences Among Outpatient Dispensing Formats .................................................... 29

2.2. Independent Pharmacies ......................................................................................................... 31
    2.2.1. Industry Position and Wholesaler Market Shares .......................................................... 31
    2.2.2. Wholesaler Services for Independent Pharmacies .......................................................... 33
    2.2.3. Franchise Programs and Marketing Groups .................................................................... 35
2.2.4. PSAOs and the Wholesalers’ Role in the Pharmacy-Payer Relationship ............................................. 36
2.2.5. Wholesaler Relationships with Pharmacy Group Purchasing Organizations ........................................ 40
2.2.6. Wholesaler Generic Source Programs for Smaller Pharmacies .......................................................... 42
2.3. Retail Chains and Mail Pharmacies ......................................................................................................... 43
2.3.1. Wholesale Suppliers to Largest U.S. Pharmacies ................................................................................. 43
2.3.2. Physical Distribution Relationships Between Wholesalers and Retail Chains ..................................... 45
2.3.3. Generic Sourcing Relationships Between Wholesalers and Large Pharmacies .................................... 46
2.4 Wholesale Suppliers to Largest U.S. Pharmaceutical Wholesalers .......................................................... 49
2.4.1. Specialty Pharmacy Market Participants .............................................................................................. 49
2.4.2. Wholesalers’ Specialty Pharmacies ..................................................................................................... 51
2.4.3. Wholesalers’ Role in Manufacturer-Defined Limited Specialty Networks ............................................. 52
Chapter 3: Channel Role for Physician Offices/Clinics and Hospitals ............................................................ 56
3.1. The Provider-Administered Drug Market ................................................................................................. 56
3.1.1. Spending and Sites of Care .................................................................................................................. 56
3.1.2. The Buy-and-Bill System .................................................................................................................... 59
3.1.3. Provider Reimbursement in the Buy-and-Bill System ....................................................................... 60
3.1.4. Group Purchasing Organizations (GPOs) .......................................................................................... 63
3.1.5. Contract Management and Chargebacks ............................................................................................ 64
3.2. Physician Offices .................................................................................................................................... 65
3.2.1. Pharmaceutical Purchasing and Distributors’ Services ..................................................................... 65
3.2.2. GPOs for Physician Practices ............................................................................................................ 67
3.2.3. Specialty Drug Dispensing by Physician Practices ............................................................................ 69
3.3. Hospitals .................................................................................................................................................. 71
3.3.1. Pharmaceutical Purchasing and Wholesalers’ Services for Hospitals ................................................. 71
3.3.2. Hospital GPOs .................................................................................................................................... 74
3.3.3. Specialty Pharmacies at Hospitals and Health Systems .................................................................... 76
3.3.4. Wholesalers and the 340B Drug Pricing Program .............................................................................. 77
SECTION II: BUSINESS ECONOMICS AND INDUSTRY TRENDS .................................................................... 81
Chapter 4: Wholesaler Profitability .................................................................................................................. 82
4.1. Sources of Wholesaler Gross Profits and Gross Margin ........................................................................ 82
4.2. Components of Buy-Side Gross Margin ................................................................................................. 83
4.2.1. Distribution Service Agreements ......................................................................................................... 84
4.2.2. Payment Discounts ................................................................. 85
4.2.3. Specialty Distribution Service Agreements ............................ 86
4.2.4. Generic Sourcing Formularies ............................................ 88
4.2.5. Wholesaler Compensation and Bona Fide Service Fees ........ 88
4.3. Sell-Side Gross Margins and Cost-Minus Discounts .................. 90
4.4. Estimates of Overall Buy-Side and Sell-Side Gross Margins ........ 91
4.5. Gross Profits of Brand vs. Generic Drugs ................................ 94
  4.5.1. Lifecycle Profits for Traditional Generic Drugs .................... 95
  4.5.2. Lifecycle Profits for Provider-Administered Generic Drugs ..... 98
  4.5.3. Private Label Generic Drugs ........................................... 99
4.6. The Profit Impact of Brand-Name Drug Price Inflation ............... 100
  4.6.1. Brand-Name Drug Inflation and Wholesaler Fees ............... 100
  4.6.2. Inventory Appreciation and Revaluation ............................ 102
4.7. Operating Expenses and Operating Profit ................................ 104
Chapter 5: Financial Stability and Cash Management ....................... 107
  5.1. Debt, Coverage, and Liquidity Ratios .................................. 107
  5.2. Balance Sheet Assets ...................................................... 109
  5.3. Cash Conversion Cycle ..................................................... 110
    5.3.1. Inventory Levels and Days Inventory Outstanding .................. 113
    5.3.2. Accounts Receivable and Days Sales Outstanding ............. 114
    5.3.3. Accounts Payable and Days Payable Outstanding ............. 115
  5.4. Uses of Cash ...................................................................... 116
  5.5. Return on Invested Capital .............................................. 117
  5.6. Stock Market Performance ............................................... 117
Chapter 6: Forces of Change for Drug Distribution ........................... 120
  6.1. The Outlook to 2021 ......................................................... 121
    6.1.1. The Outlook for U.S. Pharmaceutical Spending and Wholesaler Revenues 121
    6.1.2. The Outlook for Brand-Name Drug Prices .................... 122
  6.2. Deflation of Generic Drug Prices ....................................... 124
  6.3. Evolution of Traditional and Specialty Dispensing Channels .... 126
    6.3.1. Pharmacy Market Evolution ........................................ 126
    6.3.2. Retail Pharmacies ...................................................... 127
6.3.3. Specialty Pharmacies ........................................................................................................ 128
6.3.4. Provider-Operated Specialty Pharmacies ...................................................................... 130
6.4. Challenges to Physician Buy-and-Bill ............................................................................... 132
  6.4.1. Hospital Acquisition of Physician Practices and Shifting Sites of Drug Administration ......................................................................................................................... 132
  6.4.2. Specialty Pharmacy Displacement of Buy-and-Bill Channels .................................. 136
6.5. The Impact of Biosimilars .................................................................................................... 142
  6.5.1. Update on the Biosimilar Market ................................................................................ 142
  6.5.2. Biosimilars Under the Pharmacy Benefit ................................................................. 142
  6.5.3. Biosimilars Under the Medical Benefit ....................................................................... 145
SECTION III: BIG THREE WHOLESALER PROFILES ................................................................. 150
Chapter 7: AmerisourceBergen Corporation ............................................................................ 151
  7.1. Business Overview ........................................................................................................ 151
    7.1.1. Company Information ............................................................................................ 151
    7.1.2. Company History .................................................................................................. 151
    7.1.3. Acquisitions and Divestitures .............................................................................. 152
    7.1.4. Business Segments ............................................................................................... 153
  7.2. Profitability ..................................................................................................................... 156
    7.2.1. Overall Pharmaceutical Distribution .................................................................... 156
    7.2.2. Profitability by Business Sub-Segment ................................................................ 157
  7.3. Customers ....................................................................................................................... 158
    7.3.1. The 10 Largest Customers .................................................................................... 158
    7.3.2. Walgreens Boots Alliance ..................................................................................... 160
    7.3.3. Express Scripts ...................................................................................................... 162
  7.4. Growth Trends ............................................................................................................... 163
    7.4.1. Distribution Company Growth Trends .................................................................. 164
    7.4.2. Specialty Group Trends ....................................................................................... 165
    7.4.3. MWI Animal Health ............................................................................................. 166
Chapter 8: Cardinal Health ........................................................................................................ 168
  8.1. Business Overview ........................................................................................................ 168
    8.1.1. Company Information .......................................................................................... 168
    8.1.2. Company History .................................................................................................. 168
    8.1.3. Recent Acquisitions .............................................................................................. 168
LIST OF EXHIBITS

Exhibit 1: Full-Line Wholesale Revenues, by Type of Customer, 2015 ..................................................8
Exhibit 2: Full-Line Wholesalers, Inventory Levels vs. Product Sales, by Product Type, 2015 ......................9
Exhibit 3: Full-Line Wholesalers, Inventory Levels vs. Product Sales, by Product Type, 2011 vs. 2015 ...........9
Exhibit 4: Specialty Distributor Revenues, by Type of Customer, 2015 ..................................................10
Exhibit 5: Specialty Distributor Sales, by Therapeutic Area, 2015 .............................................................11
Exhibit 6: Timeline of DSCSA Requirements for Wholesale Distributors, 2013-2023 .........................11
Exhibit 7: Unbranded and Branded Generics, Share of U.S. Prescriptions, 2003-2021F .........................14
Exhibit 8: Allowance for Doubtful Accounts, by Company, 2017 ..............................................................19
Exhibit 9: U.S. Drug Distribution and Related Revenues at Big Three Wholesalers, Calendar Year 2016 .......21
Exhibit 11: The U.S. Pharmacy Distribution and Reimbursement System for Patient-Administered, Outpatient
Brand-Name Drugs.................................................................................................................................25
..............................................................................................................................................................28
Exhibit 13: Average Annual Number of Prescriptions per Pharmacy, by Retail Dispensing Format, 2016 .....30
Exhibit 14: Average Annual Prescription Revenue per Pharmacy Outlet, by Retail Dispensing Format, 2016 ..30
Exhibit 15: Number of Independent Pharmacies, 1991-2016 ..................................................................31
Exhibit 16: Estimated Drug Sales and Market Share with Independent Pharmacies, by Wholesaler, 2016 .....33
Exhibit 17: U.S. Pharmacy Franchise and Marketing Programs, 2016 ...........................................................35
Exhibit 18: Consumer Satisfaction with Wholesalers’ Pharmacy Group vs. Other Dispensing Formats, 2017 ..36
Exhibit 19: Largest Pharmacy Services Administration Organizations, by Members and Ownership, 2017.....39
Exhibit 20: Pharmacy Buying Groups and Primary/Preferred Wholesaler Relationships, by Number of
Pharmacies, 2017..................................................................................................................................41
Exhibit 21: Wholesaler Generic Source Programs, Number of SKUs and Manufacturers, 2011-2015 .........42
Exhibit 22: Largest U.S. Pharmacies and Their Primary Wholesale Suppliers, 2016 .................................44
Exhibit 23: Alignment Between the Big Three Wholesalers and Top Five Pharmacies .................................44
Exhibit 24: Full-Line Wholesaler Sales to Retail Chain Warehouses, 2008 to 2016E ...............................45
Exhibit 25: Share of U.S. Generic Purchasing Volume, by Organization, 2017 .............................................47
Exhibit 26: Specialty Drug Prescription Revenues, by Dispensing Format, 2016 .........................................50
Exhibit 27: Prescription Revenues and Market Share from Specialty Pharmaceuticals, by Company, 2016 .....51
Exhibit 28: Alternative Channels to Specialty Pharmacies in Limited Dispensing Networks ...................53
Exhibit 29: Diplomat Pharmacy, Drug Purchases, by Supplier, 2012-2016 .............................................54
Exhibit 30: Medical Benefit Spending on Provider-Administered Drugs, by Drug Category and Payer, 2015 ...57
Exhibit 31: Commercial Medical Benefit Spending for Outpatient Specialty Drugs, by Site of Care, 2011 vs. 2015 ...........................................................................................................................................58
Exhibit 91: Medicare Payment Rate Per Unit, Remicade vs. Biosimilars, 2016-2017.................................148
Exhibit 93: AmerisourceBergen, Estimated Revenues and Operating Profit, by Segment, FY2017E ................158
Exhibit 94: AmerisourceBergen, Top 10 U.S. Drug Distribution Customers, FY2017 ........................................159
Exhibit 95: AmerisourceBergen, Revenues from Walgreens Boots Alliance, 2014-2017E .................................160
Exhibit 96: AmerisourceBergen, Days Sales Outstanding from Walgreens vs. All Other Customers, 2014-2017 ..........................................................................................................................161
Exhibit 98: AmerisourceBergen, Revenues by Major Business Segment and Customer, FY2012 vs. FY2017E 164
Exhibit 100: AmerisourceBergen Specialty Group, Revenues and Growth, 2012-2017E ..................................165
Exhibit 103: Cardinal Health, Estimated Revenues and Operating Profit, by Segment, FY 2017 .......................172
Exhibit 104: Cardinal Health, Top 10 U.S. Drug Distribution Customers, FY2017 ..............................................173
Exhibit 105: Cardinal Health, Revenues from CVS Health, 2013-2017 ............................................................175
Exhibit 106: Cardinal Health, Days Sales Outstanding from CVS Health vs. All Other Customers, 2013-2017 176
Exhibit 110: McKesson, Estimated Revenues and Operating Profit, by Segment, FY 2017 ............................187
Exhibit 111: McKesson, Top 10 U.S. Drug Distribution Customers, FY2017 .....................................................188
Exhibit 112: McKesson, Revenues from CVS Health, 2013-2017 .....................................................................189
Exhibit 113: McKesson, Days Sales Outstanding from CVS Health vs. All Other Customers, 2013-2017 .........191
Exhibit 115: McKesson Health Mart, Store Count and Change, 2007 to 2017 ..................................................193
Exhibit 116: McKesson’s OneStop Generic Program, Revenue Growth Rate, 2010-2017E ..............................193
Exhibit 117: McKesson Europe, Revenues and Gross Profit, by Operating Segment, 2017 .............................195